HBeAg阴性慢性乙型肝炎的诊治进展

陈华仙; 韦嘉

doi:10.3969/j.issn.1001-5256.2020.07.035

HBeAg阴性慢性乙型肝炎的诊治进展

DOI: 10.3969/j.issn.1001-5256.2020.07.035

陈华仙,
韦嘉

1. 昆明医科大学
2. 昆明医科大学第四附属医院感染-肝病科

基金项目:

云南省第二人民医院病毒性肝炎及相关肝病研究省创新团队(2015HC019)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1028
- HTML全文浏览量: 42
- PDF下载量: 217
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Advances in the diagnosis and treatment of HBeAg-negative chronic hepatitis B

1. Kunming Medical University, Kunming 650000, China
2. Department of Infectious Diseases and Hepatology, The Fourth Affiliated Hospital of Kunming Medical University, Kunming 650000, China

Research funding:

摘要

摘要:
慢性乙型肝炎(CHB)是我国最常见的慢性传染病之一,其中HBeAg阴性CHB的患病率正在增加,对我国的卫生安全造成严重危害。综合HBeAg阴性CHB的发病机制、诊疗等方面,系统回顾了近年来的临床研究进展,对HBeAg阴性CHB诊疗的新进展进行综述。
- 乙型肝炎,慢性 /
- 乙型肝炎e抗原 /
- 诊断 /
- 治疗学
Abstract:
Chronic hepatitis B( CHB) is one of the most common chronic infectious diseases in China,and the prevalence rate of HBeAg-negative CHB has been increasing year by year,causing serious harm to the security of public health in China. With reference to the pathogenesis,diagnosis,and treatment of HBeAg-negative CHB,this article reviews the clinical research advances in recent years and summarizes the new advances in the diagnosis and treatment of HBeAg-negative CHB.
- hepatitis B,chronic /
- hepatitis B e antigens /
- diagnosis /
- therapeutics

HTML全文

参考文献(30)

[1]SCHWEITZER A,HORN J,MIKOLAJCZYK RT,et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection:A systematic review of data published between 1965 and 2013[J].Lancet,2015,386(10003):1546-1555．

[2]World Health Organizatin.Global hepatitis report,2017[R].Geneva:WHO,2017．

[3]JIANG M,GONG X,XIAO XQ,et al.Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha2b[J].Int J Virol,2019,26(5):293-298.(in Chinese)蒋敏，龚兴，肖新强，等．血清miRNA-122-3p在聚乙二醇干扰素-α2b治疗CHB患者中表达的研究[J]．国际病毒学杂志，2019,26(5):293-298．

[4]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4．

[5]LU FM,LI T,LIU S,et al.Epidemiology and prevention of hepatitis B virus infection in China[J].J Viral Hepat,2010,17(Suppl 1):4-9．

[6]FUNG J,SETO WK,LAI CL,et al.Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B:Implications for antiviral therapy[J].J Hepatol,2011,54(2):195-200．

[7]WANG JY,CHEN XY.Antiviral therapy for HBe Ag-negative chronic hepatitis B[J/CD].Chin J Liver Dis(Electronic Version),2017,9(4):38-42.(in Chinese)王静月，陈新月．HBe Ag阴性慢性乙型肝炎抗病毒治疗研究进展[J/CD]．中国肝脏病杂志(电子版)，2017,9(4):38-42．

[8]YAN YJ,CHEN XY.Pathogenesis and clinical features of HBe Agnegative chronic hepatitis B[J].Beijing Med J,2014,36(12):1047-1049.(in Chinese)闫一杰，陈新月．乙肝e抗原阴性慢性乙型肝炎的形成机制和临床特点[J]．北京医学，2014,36(12):1047-1049．

[9]HUNT CM,MCGILL JM,ALLEN MI,et al.Clinical relevance of hepatitis B viral mutations[J].Hepatology,2000,31(5):1037-1044．

[10]KUSUMOTO K,YATSUHASHI H,NAKAO R,et al.Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B[J].J Gastroenterol Hepatol,2008,23(5):790-793．

[11] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2019 update[J].J Clin Hepatol,2019,35(12):2648-2669.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2648-2669．

[12]RIBEIRO RM,GERMANIDIS G,POWERS KA,et al.Hepatitis Bvirus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections[J].J Infect Dis,2010,202(9):1309-1318．

[13]BEKKU D,ARAI M,IMAZEKI F,et al.Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B[J].JGastroenterol Hepatol,2011,26(1):122-128．

[14]TERRAULT NA,LOK A,MCMAHON BJ,et al.Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018hepatitis B guidance[J].Hepatology,2018,67(4):1560-1599．

[15]European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B vitus infections[J].J Hepatol,2017,67(2):370-398．

[16]MOUCARI R,MACKIEWICZ V,LADA O,et al.Early serum HB-s Ag drop:A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBe Ag-negative patients[J].Hepatology,2009,49(4):1151-1157．

[17]TSENG TC,LIU CJ,YANG HC,et al.Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load[J].Hepatology,2012,55(1):68-76．

[18]TAKKENBERG RB,JANSEN L,de NIET A,et al.Baseline hepatitis B surface antigen(HBs Ag)as predictor of sustained HBs Ag loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir[J].Antivir Ther,2013,18(7):895-904．

[19] LI H.Simultaneous or sequential combination therapy with nucleos(t)ide analogues and interferon-αfor chronic hepatitis B in a real world[D].Wuhan:Huazhong University of Science and Technology,2017.(in Chinese)李红．慢乙肝患者同步/序贯联合核苷(酸)类似物和干扰素-α治疗的临床研究[D]．武汉:华中科技大学，2017．

[20]Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960．

[21]LEVRERO M,POLLICINO T,PETERSEN J,et al.Control of ccc D-NA function in hepatitis B virus infection[J].J Hepatol,2009,51(3):581-592．

[22]CHEVALIEV S,HEZODE C,BAHRAMI S,et al.Long-term hepatitis B surface antigen(HBs Ag)kinetics during nucleoside/nucleotide analogue therapy:Finite treatment duration unlikely[J].J Hepatol,2013,58(4):676-683．

[23]Chinese Society of Infectious Disease,Chinese Society of Hepatology,Chinese Medical Association.The expert consensus on functional cure of chronic hepatitis B[J].J Clin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]．临床肝胆病杂志，2019,35(8):1693-1701．

[24]PICCOLO P,LENCI I,DEMELIA L,et al.A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B[J].Antivir Ther,2009,14(8):1165-1174．

[25]TANGKIJVANICH P,CHITTMITTRAPRAP S,POOVORAWAN K,et al.A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBe Ag-negative chronic hepatitis B:Role of host and viral factors associated with treatment response[J].J Viral Hepat,2016,23(6):427-438．

[26]STELMA F,van der REE MH,JANSEN L,et al.HBs Ag loss after peginterferon-nucleotide combination treatment in chronic hepatitis Bpatients:5 years of follow-up[J].J Viral Hepat,2017,24(12):1107-1113．

[27]LAMPERTICO P,BRUNETTO MR,CRAXA,et al.Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B'e'antigen-negative chronic hepatitis Bgenotype D[J].J Vira I Hepat,2019,26(1):118-125．

[28]WANG JB,KANG HY,CAO XG,et al.The effect of LAM or ADVadd-on therapy for HBe Ag negative chronic hepatitis B patients with suboptimal response to PEG-IFN[J].Int J Virol,2015,22(5):310-314.(in Chinese)王建彬，康海燕，曹雪改，等．聚乙二醇干扰素应答不佳HBe Ag阴性慢性乙肝患者加用拉米夫定或阿德福韦酯疗效观察[J]．国际病毒学杂志，2015,22(5):310-314．

[29]TATSUKAWA Y,TSUGE M,KAWAKAMI Y,et al.Correction:Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBeantigen-negative chronic hepatitis B patients:A pilot study[J].Antivir Ther,2019,23(8):709．

[30] ZHANG WH,ZHANG DZ,DOU XG,et al.Consensus on pegylated interferon alpha in treatment of chronic hepatitis B[J].Chin J Hepatol,2017,25(9):678-686.(in Chinese)张文宏，张大志，窦晓光，等．聚乙二醇干扰素治疗慢性乙型肝炎专家共识[J]．中华肝脏病杂志，2017,25(9):678-686.

施引文献

资源附件(0)

访问统计